Krystal Biotech, based in Pittsburgh, focuses on developing genetic medicines for diseases with high unmet needs, employing 229 staff since its IPO in September 2017. Its products include VYJUVEK for DEB and others targeting cystic fibrosis and solid tumors.
KRYS filed a patent for "interleukin-2 and interleukin-12 for cancer therapy" on Thu, March 2, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
